The stromal stem cell fraction of many tissues and organs has demonstrated to exhibit stem cell properties such as the capability of self-renewal and multipotency, allowing for multilineage differentiation. In this study, we characterize a population of stromal stem cells derived from menstrual blood (MenSCs). We demonstrate that MenSCs are easily expandable to clinical relevance and express multipotent markers such as Oct-4, SSEA-4, and c-kit at the molecular and cellular level. Moreover, we demonstrate the multipotency of MenSCs by directionally differentiating MenSCs into chondrogenic, adipogenic, osteogenic, neurogenic, and cardiogenic cell lineages. These studies demonstrate the plasticity of MenSCs for potential research in regenerative medicine.
INTRODUCTION
cells that can be safely obtained, in a renewable fashion, and maintain potency to differentiate.
Recently, stromal cells have been identified in endo-Embryonic stem cells (ESCs) have the totipotent ability to differentiate into any cell type derived from all metrial tissue (3, 19) . However, obtaining the cells directly would be a very invasive procedure. The endome-three germ layers (14, 22) . However, the potential for teratomas, along with limited availability of ESCs for trial lining of the uterus has a remarkable capacity for regeneration. During each menstrual cycle there is vast large-scale clinical use, currently limit them strictly for scientific research. However, with the vast number of growth of tissue and blood vessels, which is shed at the end of the cycle. The shed blood and tissue contain a patients with a myriad of diseases, additional stem cell sources with practical clinical application are being heterogeneous population of cells including some with regenerative capacity (5) . The uterine stromal cells have sought. Many other sources of stem cells have been identified that are already being used in early phase clin-similar multipotent markers commonly found in bone marrow mesenchymal stem cells and may actually origi-ical trials, including heart failure (18), spinal cord injury (17), and bone and cartilage repair (24) . The stromal cell nate in part from bone marrow (12, 20, 21) . Important markers for determining multipotency are Oct-4 and fraction of many tissues and organs has shown in vitro multipotency by differentiating into neurogenic, cardio-SSEA-4, which are found to be expressed in many multipotent and pluripotent stem cells including ESCs, genic, osteogenic, adipogenic, and chrondrogenic cell types (4, 6, 23, 24, 26) . The fact that stromal cells can dif-along with the cell surface marker c-kit (CD117) (8, 10, 25) . In order to evaluate the practicality of obtain-ferentiate into ectoderm and mesoderm lineages further validates their multipotency. The question then becomes ing multipotent stem cells from the uterus, in a safe and reproducible manner, we analyzed the shed menstrual whether there is a source of multipotent stromal stem blood and tissue to identify stromal cells (MenSCs). We method and stained with trypsin Wright's stain protocol to produce G-banding. present here a population of MenSCs that express the multipotent markers Oct-4, SSEA-4, and c-kit, along RNA Extraction and RT-PCR Analysis with their ability to be directionally differentiated in vitro into multiple cell lineages derived from mesoderm Total cellular RNA was isolated using RNeasy mini kit (Qiagen Inc., Valencia, CA). Total cellular RNA was and ectoderm and the ability to be easily expanded.
collected from approximately 100,000 cells per experi-MATERIALS AND METHODS ment. To eliminate DNA contamination, the samples Cell Procurement and Processing were treated with 2.0 U of DNase I (Invitrogen) at 37°C for 15 min followed by inactivation with the addition of An endometrial/menstrual cell sample was procured EDTA 2 mM at 65°C for 10 min. The samples were by using a Divacup (Kitchener, ON) during the first few concentrated by ethanol precipitation and resuspended days of a menstrual cycle. The cells were harvested with in RNase-free water. Prior to cDNA synthesis, the samthe informed consent of the donor as approved by an ples were screened for genomic DNA contamination by institutional review board. The cells were transferred in PCR on RT controls. Total RNA was transcribed into phosphate-buffered saline (PBS) with penicillin/strepto-cDNA using the Omniscript RT kit and later purified mycin and heparin. The sample was shipped at 4°C until with the QIAquick PCR purification kit (Qiagen Inc.). it reached the processing laboratory within 24-48 h after For each PCR reaction, 20 ng of cDNA template was procurement. The sample was centrifuged and supernaused in a 25-µL reaction volume with HotStar Taq Plus tant was evaluated for bacteria. The cells were then culand Quantitect Primers (Qiagen Inc.). All targets were tured.
amplified at an annealing temperature of 55°C for 30 Cell Culture Method cycles. Amplification products were identified by size on a 2% agarose gel. Cells were cultured with Chang Medium and seeded in a culture flask to obtain adherent cells (7) . Chang Flow Cytometry Medium is composed of MEM alpha medium (In-For cell surface antigen analysis after c-kit enrichvitrogen, Carlsbad, CA), Chang B (basal) (18% v/v) (Irment, the cells were harvested, washed in ice-cold vine Scientific, Santa Ana, CA), Chang medium C from blocking buffer (MEM/HEPES + 2% BSA), and incu-Supplement C106 (2% v/v) (Irvine Scientific), penicilbated for 30 min on ice in blocking buffer containing the lin/streptomycin sulfate (Invitrogen), L-glutamine 2 mM specific FITC-, APC-, phycoerythrin (PE)-, or PECy5-(Invitrogen), and fetal bovine serum (FBS, 15% v/v) (Inlabeled antibodies. Antibodies for human cell surface vitrogen). Cells were cultured for 7 days at which time antigens CD9, CD29, CD34, CD38, CD44, CD45, the media was changed. On day 10 the cells were sub-CD49f, CD90, CD105, CD117, CD166, LIN, MHC I, cultured using TrypLE Express (Invitrogen) and 50,000 and MHC II were from Becton, Dickinson and Company cells were obtained. The cells were subcultured until (Franklin Lakes, NJ), while CD133 was from Miltenyi passage five, at which time the cells were processed by Biotec and SSEA-4 was from Chemicon. In all experipositive selection for c-kit+ (CD117) was performed usments, the corresponding isotype-matched antibodies ing Magnetic Micro beads (Miltenyi Biotec, Auburn, (Becton, Dickinson and Company) were used as nega-CA) according to the manufacturer's directions using tive controls. Data (20,000 events) were collected using purified mouse anti-human CD117 monoclonal antibody a FACS Canto flow cytometer (BD Biosciences, San (IgG1) with clone 104D2 (Santa Cruz Biotechnology Jose, CA) and analyzed on FACS Diva software (BD Inc., Santa Cruz, CA). Ten million cells were processed Biosciences). with 900,000 cells in the positive fraction that were cultured. The c-kit+ (CD117) cells were further subcultured Adipogenic Differentiation an additional three passages in MSC-BM medium (Lonza, Cells were plated onto 0.2% gelatin (Sigma) at Basel, Switzerland). The cells were subcultured using 20,000 cells/cm 2 in hMSC Adipogenic Differentiation 0.25% trypsin (Invitrogen) and cultured on flasks and BulletKit (ADB) (Cambrex, East Rutherford, NJ); ADB plates seeded at 5000-7000 cells/cm 2 . Medium was medium consisted of 1 mM dexamethasone, 0.5 mM 3changed every 2-3 days between passages after the first isobutyl-1-methyl-xanthine (IBMX), 10 µg/ml recombi-7 days of culture.
nant human insulin, 100 mM indomethacin, and 5% Karyotype Analysis FBS (Hyclone). Cells were in ADB for 7 days, in adipogenic maintenance media (AM) [DMEM-LG/GL (In-Karyotype analysis was performed at Cell line Genetics (Madison, WI) by standard cytogenetic protocol. In vitrogen) + 1% penicillin/streptomycin (Invitrogen) + 15% FBS (Hyclone) + 10 µM insulin (Sigma)] for 3-4 days, total, 50 metaphases were prepared by the air-drying and then interchanged from AM to ADB every 3-4 days
Neural Differentiation for up to 20 days.
Cells were plated onto fibronectin-coated cover slips (BD Biosciences) at 10,000 cells/cm 2 
in Neural Induction

Osteogenic Differentiation
Media (NIM) consisting of DMEM-F/12 (Invitrogen) + Cells were plated onto 0.2% gelatin (Sigma) at 1% penicillin/streptomycin + 2 mM Glutamax (Gibco) + 20,000 cells/cm 2 and treated with hMSC Osteogenic 1 × N-2 supplement (Invitrogen) plus the following con-Differentiation BulletKit (ODB) (Cambrex), ODB medition: 1) 10 or 100 ng/ml fibroblast growth factor dium consisted of 100 nM dexamethasone, 10 mM β-(bFGF) for 4 days, 2) passed 1:2 in 10 ng/ml bFGF + glycerophosphate, 0.2 mM ascorbate, and 5% FBS and 10 ng/ml platelet-derived growth factor (PDGF) + 20 were in ODB with one-half medium changes every 3-4 ng/ml epidermal growth factor (EGF) for 5 days, and 3) days for up to 20 days. 10 ng/ml bFGF + 10 ng/ml PDGF excluding EGF for 7 days totaling 16 days. Cells were cultured on fibronec-Chondrogenic Differentiation tin-coated cover slips and full medium changes occurred every 2-3 days with fresh growth factors (all from R&D Cells were plated onto 0.2% gelatin at 6,000 cells/ Systems, Inc.). cm 2 in hMSC Chondrogenic Differentiation BulletKit (CDB) (Cambrex) + 1% FBS + 20 ng/ml TGF-β3 (R&D Cardiac Differentiation Systems, Inc., Minneapolis, MN) added fresh. Cells received full medium changes every 3-4 days for 14-20
Cells were plated onto 0.2% gelatin-coated cover slips (VWR) at 30,000 cells/cm 2 and in low-adhesion days. dishes (Fischer) at 156,000 cells/cm 2 in Cardiac Media room temperature (RT). Adipogenic induced cells were stained for fat vacuoles using the oil red O staining kit consisting of DMEM-LG + 1% penicillin/streptomycin + 2 mM Glutamax (Gibco) + 1% FBS (Hyclone). After 2 (American Master Tech Scientific, Lodi, CA). Briefly, cells were washed with 70% ethanol (EMD Chemicals days, cell aggregates were plated onto the cell monolayer. After 2 days medium was changed to Cardiac Me-Inc., San Diego, CA), incubated for 10 min at RT with oil red O, and counterstained with Modified Mayer's dium with either 8 µM 5-aza-2′-deoxycytidine (Aza) or 400-800 µM S-nitroso-N-acetylpenicillamine (SNAP) Hematoxylin (MMH) (American Master Tech Scientific, Lodi, CA). Osteogenic-induced cells were stained for (both from Sigma). Full media changes occurred with fresh Aza and one half medium changes with fresh calcium deposits using alizarin red S (Fisher Scientific, Pittsburg, PA). Briefly, cells were washed two times SNAP every 2-3 days for 12 days. Some MenSC cultures were induced to undergo cardiogenesis by allowing with water, incubated 1 h at RT with 0.0075% alizarin red S (Fisher Scientific) diluted in dH 2 O, and counter-the cultures to become overcrowded; medium was changed every 2-3 days.
stained with MMH. Chondrogenic-induced cells were stained for sulfated proteoglycans using alcian blue Immunocytochemistry (Sigma). Briefly, cells were incubated with 1% alcian blue (Sigma) in 0.1 N HCl (Sigma) for 1 h RT, washed All cells were fixed in 4% paraformaldehyde (Electron Microscopy Science, Hatfield, PA) for 10 min at one time with 0.1 N HCl (Sigma) for 5 min at RT, and counterstained with MMH. For antibody staining, cells Nuclei were stained using DAPI (Invitrogen). The specificity of antibodies was tested using human embryonic were washed in PBS and fixed in 4% paraformaldehyde for 10 min at room temperature (RT). Blocking solution, stem cell cultures and human neural and cardiac cells as positive controls. Negative controls for staining included PBS/2%BSA/10% goat serum/Triton X-100 0.2%, was applied for 1 h at RT followed by incubation with pri-corresponding IgG isotype control or omission of primary antibody. Fluorescence was analyzed using an mary antibody overnight at 4°C. After washing in PBS/ Triton X-100 0.2%, cells were incubated with secondary Olympus BX-61 microscope with SlideBook image software while mesodermal staining was analyzed using a antibody for 1 h at RT, washed in PBS, and mounted in MenSCs rapidly expand at a doubling rate of 24-36 h; starting with 50,000 cells we obtained 48,000,000 by con), and cardiac-actin (1:100) (RDI, Concord, MA). day 26 ( Fig. 1a ) and they maintained diploid cells with-MenSCs Differentiate Into Mesodermal Lineage out chromosomal aberrations as determined by karyo-Stromal stem cells have the ability to differentiate type analysis at passage 12 (Fig. 1d) . Moreover, RTinto mesoderm tissues such as cartilage, adipose, and PCR data demonstrated that MenSCs expressed the bone. MenSCs were induced to the adipogenic lineage multipotent marker Oct-4 at passage 12, but not SOX-2 (Fig. 3b ), chondrogenic lineage (Fig. 3d) , and osteogenic or Nanog (Fig. 1b) . Flow cytometric analysis illustrated lineage differentiation (Fig. 3f ). All displayed specific that MenSCs were positive for stromal cell and/or meshistological characteristics such as fat vacuoles found in enchymal stem cell markers such as CD44, CD105, adipocytes, sulfated proteoglycans staining for cartilage, CD166, CD90, CD49f, MHC I, CD29, and CD9 while and calcium deposits for bone. Figure 3a -d are negative negative for CD38, CD133, CD45, CD34, MHC II, and controls. These data demonstrate that MenSCs differen-LIN, and mildly positive for CXCR4 related to stem cell tiate into mesodermal tissues at varying degrees; for exhoming. In addition, flow cytometric analysis confirmed ample, 40-50% of MenSCs differentiated to chondrothat MenSCs highly expressed the pluripotent marker genic lineage, 60-70% for adipogenic, and 45% for SSEA-4 and c-kit+ (CD117) (Fig. 1c) . Also, SSEA-4 osteogenic lineages, all similar to or slightly better than and c-kit+ were colocalized on isolated clones from bone marrow-derived MSCs. MenSCs (Fig. 2) . Cultured MenSCs appeared to have MenSCs Differentiate Into Neural Lineage stromal cell morphology (Fig. 1e) . These data demonstrate that MenSCs are expandable and express multipo-In order to demonstrate the plasticity of MenSCs, we differentiated cells toward ectodermal lineage and as-tent stem cell markers.
sessed their cellular and molecular marker expression. SNAP (Fig. 5a-c) . RT-PCR data support immunocytochemistry findings by demonstrating that differentiated When MenSCs were placed into medium containing FGF for 4 days, followed by the addition of FGF, MenSCs express cardiac markers at the RNA level ( Fig.  5d ), when cells are overgrown with MenSCs cell aggre-PDGF, and EGF for 7 days, then cultured in FGF and PDGF excluding EGF for 5 days the cells expressed oli-gates. These data confirm that MenSCs express cardiogenic markers at the cellular and molecular level at a godendroglial markers O4 and GalC (Fig. 4a-c) , the mature neuronal marker Map-2 (Fig. 4d) , and Vimentin rate of 50-60%, which is similar to bone marrow derived MSCs. (Fig. 4f ). Cells also expressed the astrocyte marker GFAP (Fig. 4e ). RT-PCR data supports the immunocy-Telomerase Activity tochemistry data by confirming that MenSCs express several neural markers at the RNA level ( Fig. 4g ), in-
The MenSCs maintain greater than 50% of their tecluding Nestin, NCAM, and Nurr-1. These data demonlomerase activity even at passage 12 when compared to strate the plasticity of MenSCs and the potential for difhuman embryonic stem cells, which is much better than ferentiation into multiple neural phenotypes at a rate of bone marrow-derived MSCs (Fig. 6 ). 45-50%, which is similar to bone marrow-derived DISCUSSION MSCs.
Stromal stem cells have been shown to have great MenSCs Differentiate Into Cardiogenic Lineage potential for future use in clinical translation of regenerative therapies (23, 24, 26) . We have presented a popula-MenSCs can be differentiated into cells of the cardiac lineage using two different techniques. Immunocyto-tion of stromal cells isolated from human menstrual blood (MenSCs). The MenSCs are characterized at both chemistry demonstrated positive staining for the cardiac markers actin, troponin, and connexin 43 when the cells the cellular and molecular level, along with the ability to easily expand and differentiate. This study demon-were differentiated using either 8 µM Aza or 800 µM strates that MenSCs are a unique cell population that capacity to differentiate into cell types derived from multiple germ layers. The transcription factor Oct-4 and can be safely isolated and provide an expandable source of stem cells from child-bearing aged women. The ex-SSEA-4 both are markers expressed by human embryonic stem cells (11), which are also highly expressed in pression of multipotent markers Oct-4, SSEA-4, and ckit (CD117) in the MenSCs is not common in most other our MenSCs, and may explain the rapid cell expansion (Fig. 1 ). It may also explain the ability to be direction-adult stem cells. We have isolated clones with positive c-kit and SSEA-4 colocalization (Fig. 2 ). This unique ally differentiated into several cell types ( Fig. 3-5 ). The differentiated cell types demonstrate plasticity of the population of MenSCs is different than one recently described by Cui et al. (5) , which demonstrated skeletal MenSCs by the fact that cells have not only phenotypic cell surface markers by flow cytometry and immunocy-muscle differentiation where they found menstrual blood cells expressing the following flow profile: positive tochemistry but also mRNA expression. The need for regenerative therapies incorporating cells CD13, CD29, CD44, CD54, CD55, CD59, CD73, CD90, CD105, MHC-I and negative CD14, CD31, that have the ability to engraft and differentiate is vast. However, the ideal cell would also have the ability to be CD34, CD45, CD50, c-kit, CD133, MHC-II. Our cells ( Fig. 1 ) have the multipotent markers mentioned above, used in an allogeneic manner. Mesenchymal stem cells derived from bone marrow are currently in clinical trials which are absent in the cells identified and used by Cui et al. (5) . Also, the MenSCs appear to have similar char-after demonstrating safety and efficacy in animal models for allogeneic use due to their immunosuppressive proper-acteristics as the human endometrial stem cells identified by Cho et al. ties (13, 16 ). Due to their ease of collection and isolation, MenSCs would be a great potential source of multipotent (15) with Oct-4, clonally expanded by Gargett et al. (9) , and the mouse endometrial stem cells identified by Cer-cells if they also exhibited these properties. Currently, we are evaluating the use of human MenSCs vello et al. (1) with both c-kit+ (CD117) and Oct-4. Thus, it could be interpreted that MenSCs are the shed in vivo for neurodegenerative and cardiovascular regenerative therapies in animal models. We are also in the version of endometrial stem cells that can be easily harvested in a noninvasive manner. The expression of process of identifying the heterogeneous mixture of cell types found in menstrual blood and evaluating better multipotent markers is indicative of cells that have the 10. Greco, S. J.; Liu, K.; Rameshwar, P. Functional similarimeans to isolate and culture pure populations of MenSCs. ferentiated from human menstrual blood.
